Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.58 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102679 | 0.86 | HTT (0.62) | CYP11B2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12300199 | 0.86 | PRKCI (0.67) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL1499643 | 0.84 | PRKCI (0.68) | MEN1KMT2AALDH1A1HTTNPC1 | |
| SCHEMBL3905888 | 0.81 | MEN1 (0.72) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL16007625 | 0.81 | MEN1 (0.76) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL5802512 | 0.81 | CYP11B2 (0.78) | CYP11B2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL15528739 | 0.80 | MEN1 (0.67) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL12469188 | 0.80 | ATG4B (0.69) | CYP11B2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30928885 | 0.79 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL30928884 | 0.79 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011509280-A | — | — | 2011-03-24 | — | — | JP | claimed |
| CN-101965341-A | Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities | CT NAT RECHSEARCH SCIENT | 2011-02-02 | — | — | CN | claimed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | claimed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | claimed |
| EP-3536691-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2022-10-05 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| US-8604063-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| CN-101965341-A | Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities | CT NAT RECHSEARCH SCIENT | 2011-02-02 | — | — | CN | disclosed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, PRPF40A | CYP11B2 1348/4885MEN1 1147/4885KMT2A 4141/4885 |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | CYP11B2 290/4885MEN1 1067/4885KMT2A 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.